The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

Volpe, Massimo; Carnovali, M; Mastromarino, Vittoria

doi:10.1042/cs20150469

Cited by 250 publications

(234 citation statements)

References 214 publications

(217 reference statements)

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…3 [39]), создавался для повышения эффективности лекарственной терапии ингибиторами РААС больных ХСН со сниженной (реду-цированной) ФВ (ХСНрФВ) и сохраненной ФВ ЛЖ (ХСНсФВ). С этой целью в последнее время выполнен ряд клинических исследований, которые позволили полу-чить представление о его клинической эффективности и безопасности применения в этих популяциях пациен-тов, включая лиц с нарушенной функцией почек.…”

Section: Discussionunclassified

Clinical efficacy of dual inhibitor of neprilisin and AT1‑angiotensin receptors LCZ696 (sakubitril/valsartan) in chronic heart failure patients with impaired renal function

Кузьмин¹,

Zezha²,

Belyanin³

et al. 2017

RHFJ

View full text Add to dashboard Cite

Резюме В обзоре представлены сведения об участии натрийуретических пептидов в нейрогормональном механизме, препятствующем повреждению сердца и почек у больных ХСН, и результаты, полученные при оценке клинической эффективности LCZ696 (сакубитрил / валсартан) в этой популяции пациентов, включая лиц с нарушенной функцией почек.Kuzmin O. B

show abstract

Section: Discussionunclassified

Clinical efficacy of dual inhibitor of neprilisin and AT1‑angiotensin receptors LCZ696 (sakubitril/valsartan) in chronic heart failure patients with impaired renal function

Кузьмин¹,

Zezha²,

Belyanin³

et al. 2017

RHFJ

View full text Add to dashboard Cite

show abstract

“…The upregulation of the neurohormonal system in congestive heart failure is well known [18,19]. The coagulation pathway is affected most possibly secondary to the activated sympathetic system and proinflammatory molecules.…”

Section: Discussionmentioning

confidence: 99%

Correlation of Coagulation Pathway Parameters with BNP, Ejection Fraction and NYHA Class in Heart Failure

Nair

Góngora

2016

ICFJ

View full text Add to dashboard Cite

Abstract BackgroundThe upregulation of inflammation and coagulation in addition to the sympathetic nervous system is known and reported in congestive heart failure. This study was undertaken to assess the correlations of the changes in coagulation parameters with functional class, ejection fraction and brain natriuretic peptide levels. MethodsA small prospective study was conducted in dilated cardiomyopathy (DCM) patients.The protocol was approved by the Hospital IRB ( Scott and White Memorial, Temple, TX 76508). Statistical analysis was conducted using the online Vassar stats system . Spearman’s rank order correlation was derived for all the correlations mentioned in this paper. ResultsPT, PTT, INR and d-dimer levels were significantly different in the two groups and correlated positively and significantly with BNP and New York Heart Association class . Statistically significant negative correlation was noted with ejection fraction. fibrinogen levels did not correlate significantly with BNP, New York Heart Association class or ejection fraction. ConclusionsCoagulation pathway parameters correlate significantly with BNP, functional class and ejection fraction in this study. The study is limited by its size and the fact that only dilated non- ischemic cardiomyopathy patients were included. Larger studies are required to further understand the complex interactions of biochemical pathways noted in heart failure.

show abstract

“…These beneficial effects have elicited increasing attention on the treatment of HF by targeting the natriuretic peptide system 55. However, just as a coin has two sides, BNP is no exception.…”

Section: Evidence For Interaction Between Bnp and Treatment Effects Omentioning

confidence: 99%

New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides

Zhai

Luo

et al. 2018

J Med Genet

View full text Add to dashboard Cite

Sarcoplasmic/endoplasmic reticulum calcium ATPase 2a (SERCA2a) is a target of interest in gene therapy for heart failure with reduced ejection fraction (HFrEF). However, the results of an important clinical study, the Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial, were controversial. Promising results were observed in the CUPID 1 trial, but the results of the CUPID 2 trial were negative. The factors that caused the controversial results remain unclear. Importantly, enrolled patients were required to have a higher plasma level of B-type natriuretic peptide (BNP) in the CUPID 2 trial. Moreover, BNP was shown to inhibit SERCA2a expression. Therefore, it is possible that high BNP levels interact with treatment effects of SERCA2a gene transfer and accordingly lead to negative results of CUPID 2 trial. From this point of view, effects of SERCA2a gene therapy should be explored in heart failure with preserved ejection fraction, which is characterised by lower BNP levels compared with HFrEF. In this review, we summarise the current knowledge of SERCA2a gene therapy for heart failure, analyse potential interaction between BNP levels and therapeutic effects of SERCA2a gene transfer and provide directions for future research to solve the identified problems.

show abstract

The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment

Abstract: This article overviews the natriuretic peptides (NPs) system, its role and the development of NP-based treatment of heart failure (HF).

Cited by 250 publications

References 214 publications

Clinical efficacy of dual inhibitor of neprilisin and AT1‑angiotensin receptors LCZ696 (sakubitril/valsartan) in chronic heart failure patients with impaired renal function

Clinical efficacy of dual inhibitor of neprilisin and AT1‑angiotensin receptors LCZ696 (sakubitril/valsartan) in chronic heart failure patients with impaired renal function

Correlation of Coagulation Pathway Parameters with BNP, Ejection Fraction and NYHA Class in Heart Failure

New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides

Contact Info

Product

Resources

About